Skip to main content

Table 4 Adjusted associations of residency and secondary exposures with treatment success and loss to follow-up (n = 5490)

From: Tuberculosis among economic migrants: a cross-sectional study of the risk of poor treatment outcomes and impact of a treatment adherence intervention among temporary residents in an urban district in Ho Chi Minh City, Viet Nam

 Treatment successLoss to follow-up
aRR‡95% CIp-valueÞaOR‡95% CIp-valueÞ
Residency
 KT1¥1.00  1.00  
 KT20.95[0.88, 1.02]0.1631.86[1.03, 3.36]0.041
 KT31.01[0.97, 1.05]0.6850.59[0.30, 1.17]0.134
 KT40.95[0.92, 0.99]0.0101.98[1.44, 2.72]< 0.001
Sex
 Male¥1.00  1.00  
 Female1.02[1.00, 1.05]0.0780.80[0.60, 1.07]0.139
Age
  < 25 years¥1.00  1.00  
 25–34 years1.00[0.97, 1.04]0.8811.00[0.68, 1.46]0.982
 35–44 years1.01[0.97, 1.04]0.6220.73[0.48, 1.11]0.142
 45–54 years1.00[0.96, 1.03]0.8630.59[0.37, 0.93]0.024
  > 55 years0.93[0.89, 0.96]< 0.0010.58[0.36, 0.93]0.024
Patient type
 New¥1.00  1.00  
 Relapse0.89[0.84, 0.94]< 0.0011.09[0.69, 1.73]0.705
 Failure0.62[0.52, 0.75]< 0.0011.77[0.80, 3.95]0.160
 LTFU0.87[0.73, 1.02]0.0851.79[0.69, 4.62]0.228
 Unknown0.97[0.92, 1.02]0.1981.42[0.86, 2.36]0.171
 Transfer in0.88[0.81, 0.96]0.0031.48[0.85, 2.60]0.170
Type of TB§,Π
 AFB(+)¥1.00  1.00  
 AFB(−)1.06[1.03, 1.09]< 0.0010.79[0.55, 1.12]0.184
 EP1.05[1.02, 1.08]0.0010.77[0.55, 1.08]0.126
HIV/AIDS
 No/Unknown¥1.00  1.00  
 Yes0.77[0.73, 0.82]< 0.0012.18[1.55, 3.06]< 0.001
Diabetes
 No/Unknown¥1.00  1.00  
 Yes0.96[0.91, 1.02]0.1591.15[0.65, 2.03]0.619
  1. Notes
  2. Adjusted summary RR and OR by log binomial and logistic regression, respectively, adjusted by all other variables listed in the table;
  3. ÞWald test;
  4. ¥Referent;
  5. Failure = Retreatment after category I treatment failure; LTFU = Retreatment after loss to follow-up; Unknown = Retreatment with unknown/uncertain exposure to anti-TB drugs;
  6. §AFB(+) = Sputum smear positive; AFB(−) = Sputum smear negative; EP = Extra-pulmonary TB;
  7. Πnot included in the final convergent multivariate model with LTFU as the primary outcome
  8. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome;